| 摘要 |
FIELD: chemistry.SUBSTANCE: invention relates to compounds of formula (I)or pharmaceutically acceptable salts thereof, where Q is phenyl or pyridinyl; A is pyrazolyl or triazolyl, where each A is independently additionally unsubstituted or substituted with 1 or 2 substitutes represented by R, or A is formula (a); Vis C(R), Vis N or C(R) and Vis N; or Vis N, Vis C(R) and Vis N or C(R); Ris hydrogen, Ris hydrogen, Calkyl, -OR, -SR, aryl, selected from phenyl, heteroaryl, selected from thienyl, or cycloalkyl, selected from cyclopropyl; Ris hydrogen or aryl, selected from phenyl; Ris hydrogen or Calkyl; Ris hydrogen, Calkyl, -OH, -S(O)R, or heteroaryl, selected from tetrazolyl, where the heteroaryl is bonded to a nitrogen atom through a ring carbon atom; R, R, R, R, R, R, R, R, R, R, Rand R, in each case, are independently hydrogen, Calkyl or Chaloalkyl; and R, in each case, is independently hydrogen, Calkyl or -OH (the rest of the substitutes assume values given in the claim). The invention also relates to a pharmaceutical composition, having inhibiting action on DGAT-1, which contains a compound of formula (I), and a treatment method.EFFECT: compounds of formula (I) as DGAT-1 inhibitors are provided.16 cl, 9 dwg, 1 tbl, 127 ex |
